The Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr (SAPPHIRE): A National Study
What Is SAPPHIRE?
Inflammatory bowel disease (IBD) is a condition in which the body’s immune system reacts inappropriately and causes ongoing inflammation in the digestive tract. To manage this, many patients are often treated with immunosuppressants. Beca...
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
The purpose of this study is to learn how a new medicine called PF-08052667 works when
used by itself or together with another medicine called Bacillus Calmette Guerin (BCG),
and/or a medicine called sasanlimab.
This study is for adults who have a type of bladder c...
Age: 18 years - 66+
Gender: All
Feasibility of Timesaving When Using Histolog Confocal Laser Endomicroscopy for Margin Assessment in Prostatectomy Specimen
This study investigates a new, faster way to find cancer cells on the surface of the
prostate during radical prostatectomy surgery. A recently FDA-approved device, called the
Histolog Scanner, gives high-resolution imaging of the surface of fresh tissue using
ultra-f...
Age: 18 years - 66+
Gender: Male
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
A study of tolododekin alfa (also known as ANK-101) administered in combination with an
anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1)
antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Cohort ...
Age: 18 years - 66+
Gender: All
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
This phase III trial compares the effect of dose-escalated radiation therapy to usual
care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who
have received an initial 4-6 months of chemotherapy. Usual care options include
additional c...
Age: 18 years - 66+
Gender: All
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Researchers are looking for new ways to treat metastatic castration-resistant prostate
cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan
(also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if
people ...
Age: 18 years - 66+
Gender: Male
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate
(ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth
factor (VEGF) bispecific antibody, in participants with advanced/metastatic or
relapsed/pr...
Age: 18 years - 66+
Gender: All
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
This is a global, multicenter, open-label study that aims to assess the efficacy and
safety of zelenectide pevedotin in participants with NECTIN4-amplified recurrent,
unresectable, or metastatic breast cancer who have received prior therapy (see inclusion
criteria be...
Age: 18 years - 66+
Gender: All
Enfortumab Vedotin Plus Pembrolizumab with Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Patients with MIBC will receive 3 cycles (C1-C3) of induction enfortumab vedotin plus
pembrolizumab followed by restaging including MRI of the bladder, urine cytology, and
cystoscopy with TURBT of any visible tumor and/or resection site plus random biopsies
using a r...
Age: 18 years - 66+
Gender: All
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Patients with MIBC will receive 3 cycles (C1-C3) of induction enfortumab vedotin plus
pembrolizumab followed by restaging including MRI of the bladder, urine cytology, and
cystoscopy with TURBT of any visible tumor and/or resection site plus random biopsies
using a r...
Age: 18 years - 66+
Gender: All
Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria
The purpose of this research study is to see if a drug called ritlecitinib is safe and
effective for treating chronic spontaneous urticaria (CSU). CSU is hives and itching
lasting over six weeks. Ritlecitinib is approved by the Food and Drug Administration
(FDA) to t...
Age: 18 - 65 years
Gender: All
Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria
The purpose of this research study is to see if a drug called ritlecitinib is safe and
effective for treating chronic spontaneous urticaria (CSU). CSU is hives and itching
lasting over six weeks. Ritlecitinib is approved by the Food and Drug Administration
(FDA) to t...
Age: 18 - 65 years
Gender: All
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the
investigator's choice of therapy in participants with Metastatic Castration-resistant
Prostate Cancer.
Age: 18 years - 66+
Gender: Male
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the
investigator's choice of therapy in participants with Metastatic Castration-resistant
Prostate Cancer.
Age: 18 years - 66+
Gender: Male
E-Mindfulness Approaches for Living After Breast Cancer
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy
of two distinct digital approaches for delivering a mindfulness-based intervention: a
live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced
ver...
Age: 18 - 50 years
Gender: All
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
The goal of this observational study is to understand how genomic and epigenetic factors
contribute to resistance against chemo-immunotherapy in adults diagnosed with
extensive-stage small cell lung cancer (ES-SCLC) or metastatic large cell neuroendocrine
carcinoma (...
Age: 18 - 85 years
Gender: All
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
The goal of this observational study is to understand how genomic and epigenetic factors
contribute to resistance against chemo-immunotherapy in adults diagnosed with
extensive-stage small cell lung cancer (ES-SCLC) or metastatic large cell neuroendocrine
carcinoma (...
Age: 18 - 85 years
Gender: All
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help t...
Age: 18 years - 66+
Gender: All
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
This phase III trial compares the effect of adding tivozanib to standard therapy
pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk
renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may hel...
Age: 18 years - 66+
Gender: All
WATER IV Prostate Cancer
This is a multicenter, prospective, randomized clinical trial that aims to assess the
safety and efficacy of Aquablation Therapy in men with low-risk to intermediate to
high-risk localized prostate cancer who are candidates for, or have opted for,
prostatectomy. Part...
Age: 45 years - 66+
Gender: Male